How the Medicinal Cannabis Scheme verifies products

How the Medicinal Cannabis Scheme verifies products is narrower than medicine approval. The Medicinal Cannabis Agency checks whether evidence shows that a cannabis-derived ingredient or product meets New Zealand’s minimum quality standard. A product that passes that assessment has not automatically been shown to be safe or effective for a particular condition.

Medicinal Cannabis Scheme verification: what is checked

The minimum quality standard sits in the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. Its purpose is consistency and quality. Depending on the material and dosage form, the evidence can cover identity, active-ingredient assay, microbial contamination, heavy metals, pesticides, aflatoxins, foreign matter, loss on drying, total ash and residual solvents. Stability evidence supports the proposed shelf life and storage conditions.

The Ministry distinguishes starting material, cannabis-based ingredients and finished medicinal cannabis products. The standard does not apply in exactly the same way to every category, and the regulations contain limited exemptions. That is why a supplier must identify the correct regulatory pathway before treating a laboratory result as proof of compliance.

The compliance process in practical order

1. Classify the material and intended supply route. The applicant identifies whether the application concerns a cannabis-based ingredient, a dried product or a pharmaceutical dosage product, and whether it will be supplied domestically, imported or exported.
2. Compile manufacturing and test evidence. The Ministry’s guidance describes the required quality information, test methods, method validation and representative batch evidence. Critical testing must be conducted within the applicable quality framework.
3. Submit a product assessment. The supplier gives the Medicinal Cannabis Agency the evidence needed to assess the product against the minimum standard.
4. Answer deficiencies or change the application. Verification is evidence-based; an incomplete data package is not converted into approval by a licence, brand name or overseas sale.
5. Maintain compliance. A changed product or longer proposed shelf life can require new evidence and a further application.

This sequence is a regulatory map, not an estimate of how long an application will take.

What a verified listing means

The Ministry publishes medicinal cannabis products that meet the minimum quality standard and can be prescribed in New Zealand. The tables separate dosage products, dried flower verified for inhalation through a vaporiser, and dried flower verified for preparing tea. Some verified products may be omitted at the licence holder’s request, so absence from the public table is not by itself proof that an item failed assessment.

A specified prescriber can prescribe listed verified products without a specialist recommendation or Ministerial approval. The prescriber still decides whether a particular prescription is appropriate. Most verified products are unapproved medicines: their quality has been assessed, but their safety and efficacy have not been assessed through the Medsafe approval pathway.

Verification is not Medsafe approval

The distinction matters when reading advertising, a clinic page or a product label. “Meets the minimum quality standard” supports a quality and consistency claim. It does not support claims that the product treats anxiety, pain, insomnia or another condition. Products with consent or provisional consent for distribution under the Medicines Act have undergone a different assessment; the Ministry lists those separately.

Use three checks when evaluating a claim:

• identify whether the claim concerns quality, prescribing access or clinical benefit;
• confirm the exact product and dosage-form category on current Ministry material;
• ask the prescriber or pharmacist what evidence applies to the proposed use, not merely whether the product is verified.

A claim-checking example

Suppose a supplier says a preparation is “government approved.” Ask which decision it means. If the evidence is an entry in a minimum-quality table, the accurate claim is that the preparation meets the applicable quality standard. If the supplier claims treatment benefit, look for a separate Medsafe approval and approved indication or for clinical evidence relevant to that use. If the claim concerns who may prescribe it, check current Ministry guidance for the prescriber type and product category. One phrase should never be allowed to blur those three questions.

The durable conclusion is simple: scheme verification is a quality gateway. It is not a clinical endorsement, a guarantee of benefit or a substitute for informed prescribing.